Justices Refuse to Hear ‘Skinny Label’ Drug Patent Case

May 15, 2023 by Dan McCue
Justices Refuse to Hear ‘Skinny Label’ Drug Patent Case
(Photo by Steve PB via Pixabay)

WASHINGTON — The Supreme Court on Monday declined to review a 2020 decision by the U.S. Circuit Court of Appeals for the Federal Circuit that resulted in Teva Pharmaceuticals being found liable for $235 million for infringing on a GlaxoSmithKline heart drug patent.

The case placed a spotlight on the use of so-called “skinny labels” for generic drugs, and justices refused to weigh in on the controversy despite a request from the U.S. solicitor general.

The underlying case began in 2014 when GlaxoSmithKline sued Teva Pharmaceuticals USA over its generic version of the Glaxo heart drug Coreg, a prescription medicine used to treat the symptoms of heart failure and high blood pressure.

Teva argued in court that it followed Food and Drug Administration instructions to “carve out” from its label a single use for the drug that would not infringe on any existing patent.


The “carve out” is a key provision of the Hatch-Waxman Act of the mid-1980s, whose drafters sought to create an innovative pathway to bring low-cost generic drugs to market.

When a brand-name drug has both patented and unpatented uses, its manufacturer must tell the FDA the specific sections of its labeling that describe the patented uses. 

That allows generic manufacturers to carve out those sections and adopt a “skinny label” — one labeled for only unpatented uses. 


Teva maintains it did just that. Nevertheless, in 2017, a jury awarded GlaxoSmithKline $235 million on its patent infringement claim.

A federal judge then overturned the verdict, but the U.S. Court of Appeals for the Federal Circuit, which specializes in patent cases, reinstated it in 2020, holding that the label, coupled with Teva’s marketing materials, did encourage doctors to prescribe its drug in a way that infringed on GlaxoSmithKline’s patent.

In its petition for a Supreme Court review of the case, Teva argued that the appeals court’s “controversial” opinion would “upend the legal rules facing the modern prescription-drug marketplace, wreaking doctrinal havoc.”

“Where there was previously clarity and ‘equilibrium to the skinny-label system,’ there is now confusion and uncertainty,” Teva said. “That uncertainty discourages generics from using carve-outs, which ‘throw[s] a wrench into Congress’ design for enabling quick public access to generic versions of unpatented drugs with unpatented uses.’” 

“The ramifications of such an outcome are enormous — skinny-label launches are extraordinarily common, and they save patients and the federal government billions,” it said.

Solicitor General Elizabeth Prelogar also urged the justices to hear the case, arguing the Federal Circuit’s decision created “significant uncertainty” for generic drugmakers.


As is their custom, the justices did not explain their rationale for rejecting the case. However, the court did note that Justice Brett Kavanaugh would have granted it a review.

Dan can be reached at [email protected] and at https://twitter.com/DanMcCue

A+
a-
  • generic drugs
  • patent infringement
  • prescription drugs
  • skinny labels
  • Supreme Court
  • In The News

    Health

    Voting

    Supreme Court

    May 25, 2023
    by Tom Ramstack
    Justices Urged to Reconsider Limits on Public Officials' Defamation Suits

    WASHINGTON — A petition to the Supreme Court filed last week alleging defamation of a former Senate candidate by media... Read More

    WASHINGTON — A petition to the Supreme Court filed last week alleging defamation of a former Senate candidate by media outlets is threatening a fundamental principle of law that protects news organizations.  Former Senate candidate Don Blankenship is suing Fox News, MSNBC, CNN and other media... Read More

    May 25, 2023
    by Dan McCue
    Supreme Court Limits EPA's Power Under Clean Water Act

    WASHINGTON — The U.S. Supreme Court on Thursday narrowed the Environmental Protection Agency’s authority to regulate wetlands under the Clean... Read More

    WASHINGTON — The U.S. Supreme Court on Thursday narrowed the Environmental Protection Agency’s authority to regulate wetlands under the Clean Water Act, in the process finally ending a legal battle between the property owners and the agency that’s gone on for the past 19 years. The... Read More

    May 18, 2023
    by Dan McCue
    Supreme Court Holds Twitter, Google Not Responsible for ISIS Content

    WASHINGTON — The Supreme Court on Thursday ruled against the family of a 2015 ISIS attack victim, saying they could... Read More

    WASHINGTON — The Supreme Court on Thursday ruled against the family of a 2015 ISIS attack victim, saying they could not hold Google “directly” or “secondarily” liable for posts the terror group made to the tech giant’s YouTube site before the strike that left 130 people... Read More

    May 18, 2023
    by Dan McCue
    Justices Conclude Warhol Foundation Violated Copyright With Prince Portrait

    WASHINGTON — A divided Supreme Court on Thursday concluded that the pop artist Andy Warhol infringed on a photographer’s copyright... Read More

    WASHINGTON — A divided Supreme Court on Thursday concluded that the pop artist Andy Warhol infringed on a photographer’s copyright when he used her work as the basis for a portrait of Prince that appeared in Vanity Fair magazine. In a 7-2 ruling the justices held... Read More

    May 15, 2023
    by Tom Ramstack
    Justices to Decide if House Dems Can Get Trump Hotel Docs

    WASHINGTON — The U.S. Supreme Court agreed Monday to review a dispute over whether Congress can get access to documents... Read More

    WASHINGTON — The U.S. Supreme Court agreed Monday to review a dispute over whether Congress can get access to documents surrounding former President Donald Trump’s lease of a government building he turned into a posh Washington, D.C., hotel. The House Committee on Oversight and Reform seeks... Read More

    May 15, 2023
    by Dan McCue
    Justices Refuse to Hear 'Skinny Label' Drug Patent Case

    WASHINGTON — The Supreme Court on Monday declined to review a 2020 decision by the U.S. Circuit Court of Appeals... Read More

    WASHINGTON — The Supreme Court on Monday declined to review a 2020 decision by the U.S. Circuit Court of Appeals for the Federal Circuit that resulted in Teva Pharmaceuticals being found liable for $235 million for infringing on a GlaxoSmithKline heart drug patent. The case placed... Read More

    News From The Well
    scroll top